Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature

Kubicka‑Wołkowska,Joanna; Kędzierska,Magdalena; Lisik‑Habib,Maja; Potemski,Piotr

doi:10.3892/ol.2016.5309

Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature

Authors:
- Joanna Kubicka‑Wołkowska
- Magdalena Kędzierska
- Maja Lisik‑Habib
- Piotr Potemski
View Affiliations

Affiliations: Department of Chemotherapy, Medical University of Lodz, Copernicus Memorial Hospital, Lodz 93‑513, Poland
Published online on: October 24, 2016 https://doi.org/10.3892/ol.2016.5309
Pages: 5332-5334

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pegylated liposomal doxorubicin (PLD) is a form of doxorubicin enclosed in pegylated liposomes. In contrast to conventional doxorubicin, PLD is characterized by a lower incidence of cardiotoxicity and myelosuppression. However, it induces specific mucocutaneous side effects, particularly palmar‑plantar erythrodysesthesia (PPE). Other dermal manifestations, such as intertrigo‑like dermatitis, diffuse follicular rash, melanotic macules, maculopapular rash or recall phenomenon are less common. Mechanisms that lead to skin toxicity remain unclear, however, certain reports indicate that drug excretion in sweat, host‑vs.‑altered‑host reactions and local mechanical microtrauma play an important role in the development of cutaneous disorders. Effective preventive and curative management has not yet been established. The current study reports a case of a 55‑year‑old patient with advanced ovarian cancer who developed an uncommon diffuse maculopapular rash and severe PPE during treatment with PLD. Complete regression of the skin disorder was observed after 4 weeks. At present, palliative chemotherapy provides the opportunity to prolong life and alleviate disease symptoms, nonetheless it produces a number of adverse effects. Dermal complications may affect patient quality of life and cause therapy interruption. In the light of widespread use of PLD, skin toxicity associated with this drug creates a major problem.

View Figures

View References

1	Mangana J, Zipser MC, Conrad C, Oberholzer PA, Cozzio A, Knuth A, French LE and Dummer R: Skin problems associated with pegylated liposomal doxorubicin - more than palmoplantar erythrodysesthesia syndrome. Eur J Dermatol. 18:566–570. 2008.PubMed/NCBI
2	Green AE and Rose PG: Pegylated liposomal doxorubicin in ovarian cancer. Int J Nanomedicine. 1:229–239. 2006.PubMed/NCBI
3	Cady FM, Kneuper-Hall R and Metcalf JS: Histologic patterns of polyethylene glycol-liposomal doxorubicin-related cutaneous eruptions. Am J Dermatopathol. 28:168–172. 2006. View Article : Google Scholar : PubMed/NCBI
4	Farr KP and Safwat A: Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment. Case Rep Oncol. 4:229–235. 2011. View Article : Google Scholar : PubMed/NCBI
5	von Moos R, Thuerlimann BJ, Aapro M, Rayson D, Harrold K, Sehouli J, Scotte F, Lorusso D, Dummer R, Lacouture ME, et al: Pegylated liposomal doxorubicin-associated hand-foot syndrome: Recommendations of an international panel of experts. Eur J Cancer. 44:781–790. 2008. View Article : Google Scholar : PubMed/NCBI
6	Sobin LH, Gospodarowicz MK and Wittekind C: Ovary cancerTNM Classification of Malignant Tumours. 7th. Wiley-Blackwell; Hoboken, NJ: pp. 222–226. 2009
7	National Cancer Institute, . Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed June 14, 2010.
8	Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S and Scambia G: Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol. 18:1159–1164. 2007. View Article : Google Scholar : PubMed/NCBI
9	Skelton H, Linstrum J and Smith K: Host-vs.-altered-host eruptions in patients on liposomal doxorubicin. J Cutan Pathol. 29:148–153. 2002. View Article : Google Scholar : PubMed/NCBI
10	English JC III, Toney R and Patterson JW: Intertriginous epidermal dysmaturation from pegylated liposomal doxorubicin. J Cutan Pathol. 30:591–595. 2003. View Article : Google Scholar : PubMed/NCBI
11	Vidal C, Afonzo Y, Abal C and Rondón M: A grade IV maculopapular skin lesion associated with pegylated liposomal doxorubicin. MOJ. 2:57–59. 2012.
12	Martschick A, Sehouli J, Patzelt A, Richter H, Jacobi U, Oskay-Ozcelik G, Sterry W and Lademann J: The pathogenetic mechanism of anthracycline-induced palmar-plantar erythrodysesthesia. Anticancer Res. 29:2307–2313. 2009.PubMed/NCBI
13	Kim RJ, Peterson G, Kulp B, Zanotti KM and Markman M: Skin toxicity associated with pegylated liposomal doxorubicin (40 mg/m2) in the treatment of gynecologic cancers. Gynecol Oncol. 97:374–378. 2005. View Article : Google Scholar : PubMed/NCBI
14	Jacobi U, Waibler E, Schulze P, Sehouli J, Oskay-Ozcelik G, Schmook T, Sterry W and Lademann J: Release of doxorubicin in sweat: First step to induce the palmar-plantar erythrodysesthesia syndrome? Ann Oncol. 16:1210–1211. 2005. View Article : Google Scholar : PubMed/NCBI
15	Yokomichi N, Nagasawa T, Coler-Reilly A, Suzuki H, Kubota Y, Yoshioka R, Tozawa A, Suzuki N and Yamaguchi Y: Pathogenesis of hand-foot syndrome induced by PEG-modified liposomal doxorubicin. Hum Cell. 26:8–18. 2013. View Article : Google Scholar : PubMed/NCBI
16	Macedo LT, Lima JP, dos Santos LV and Sasse AD: Prevention strategies for chemotherapy-induced hand-foot syndrome: A systematic review and meta-analysis of prospective randomised trials. Support Care Cancer. 22:1585–1593. 2014.PubMed/NCBI
17	Templeton AJ, Ribi K, Surber C, Sun H, Hsu Schmitz SF, Beyeler M, Dietrich D, Borner M, Winkler A, Müller A, et al: Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08). Breast. 23:244–249. 2014. View Article : Google Scholar : PubMed/NCBI
18	Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL and Kim TW: Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: Results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 28:3824–3829. 2010. View Article : Google Scholar : PubMed/NCBI
19	von Gruenigen V, Frasure H, Fusco N, DeBernardo R, Eldermire E, Eaton S and Waggoner S: A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients. Cancer. 116:4735–4743. 2010. View Article : Google Scholar : PubMed/NCBI
20	Lopez AM, Wallace L, Dorr RT, Koff M, Hersh EM and Alberts DS: Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia. Cancer Chemother Pharmacol. 44:303–306. 1999. View Article : Google Scholar : PubMed/NCBI
21	Drake RD, Lin WM, King M, Farrar D, Miller DS and Coleman RL: Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies. Gynecol Oncol. 94:320–324. 2004. View Article : Google Scholar : PubMed/NCBI
22	Najem A, Deregnaucourt D, Ramdane S, Dridba M, Djouba F and Vercambre-Darras S: Intertrigo-like dermatitis with pegylated liposomal doxorubicin: Diagnosis and management. J Clin Oncol. 32:e104–e106. 2014. View Article : Google Scholar : PubMed/NCBI